UPC CoA 21/2025

Vor dem UPC: Meril Group (60 Verfahren)·Edwards Lifesciences Group (57 Verfahren)

• 2025-11-25
  Appeal RoP220.1Öffentlich

  Zusammenfassung: The Court of Appeal dismissed the Meril companies' appeals against the revocation and counterclaim revocation decisions and Edwards' appeal against the infringement decision, upholding the patent EP 3 646 825 (heart valve). Key rulings: (I–VIII) All revocation and counterclaim appeals rejected; Meril bears 60% of Edwards' costs in the revocation proceedings and Edwards bears 40% of Meril's costs. (IX–X) The infringement decision was partially set aside: the injunction and preliminary damages order do not extend to XL devices (30.5mm and 32mm) that had not been scheduled for implantation in a patient by 15 November 2024. Preliminary damages reduced to not exceed €363,000 for Meril India and Meril Germany. The value of the proceedings is €8,000,000.

  Rechtsfragen anzeigen (6)

  • Competence and same-parties rule (Art. 33(4) UPCA)
  • Admissibility of application to amend patent (R. 49.2, 50.2 RoP)
  • Claim construction
  • Inventive step
  • Scope of injunction (XL devices)
  • Preliminary damages